INTERVAL CANCERS IN THE SCREENING OF PROSTATE CANCER: RESULTS FROM THE HELSINKI AREA OF THE ERSPC STUDY

被引：0
|
作者：
Santti, H. [1 ]
Joutsi, T. [2 ]
Maattanen, L. [3 ]
Tammela, T. [4 ]
Ruutu, M. [1 ]
Auvinen, A. [5 ]
机构：
[1] Univ Helsinki, Ctr Hosp, Dept Urol, Helsinki, Finland
[2] Pori Cent Hosp, Dept Surg, Pori, Finland
[3] Finnish Canc Registry, FIN-00170 Helsinki, Finland
[4] Tampere Univ Hosp, Dept Urol, Tampere, Finland
[5] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2010年 / 9卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(10)60950-5
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：304 / 305
页数：2
相关论文
共 50 条
  • [41] Interval cancers in prostate cancer screening:: Comparing 2- and 4-year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam
    Roobol, Monique J.
    Grenabo, Anna
    Schroeder, Fritz H.
    Hugosson, Jonas
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17): : 1296 - 1303
  • [42] Prostate Cancer Screening: What We Have Learned from the PLCO and ERSPC Trials
    Jeffrey La Rochelle
    Christopher L. Amling
    Current Urology Reports, 2010, 11 (3) : 198 - 201
  • [43] A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau)
    Randazzo, Marco
    Mueller, Alexander
    Carlsson, Sigrid
    Eberli, Daniel
    Huber, Andreas
    Grobholz, Rainer
    Manka, Lukas
    Mortezavi, Ashkan
    Sulser, Tullio
    Recker, Franz
    Kwiatkowski, Maciej
    BJU INTERNATIONAL, 2016, 117 (04) : 576 - 583
  • [44] Extent of PSA contamination in the Spanish section of the European Randomised Study of Screening for Prostate Cancer (ERSPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 236 - 236
  • [45] RE: Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data
    Noordzij, M. Arjen
    Blanker, Marco H.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (06):
  • [46] Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial
    Moller, Fredrik
    Mansson, Marianne
    Wallstrom, Jonas
    Hellstrom, Mikael
    Hugosson, Jonas
    Godtman, Rebecka Arnsrud
    EUROPEAN UROLOGY, 2024, 86 (02) : 95 - 100
  • [47] The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
    Pakarainen, Tomi
    Nevalainen, Jaakko
    Talala, Kirsi
    Taari, Kimmo
    Raitanen, Jani
    Kujala, Paula
    Stenman, Ulf-Hakan
    Tammela, Teuvo L. J.
    Auvinen, Anssi
    CLINICAL CANCER RESEARCH, 2019, 25 (02) : 839 - 843
  • [48] The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
    Remmers, Sebastiaan
    Nieboer, Daan
    Roobol, Monique J.
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 51 : 1 - 6
  • [49] How to learn from interval cancers in colorectal cancer screening
    Bretthauer, Michael
    ENDOSCOPY, 2024, 56 (05) : 373 - 375
  • [50] Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
    Prorok, Philip C.
    Miller, Anthony B.
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (08) : 605 - 606
12345